FDA Approves Soliqua for Type 2 Diabetes

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

As 2016 comes to a close, we have some news in the world of diabetes medications! The FDA has recently released Soliqua 100/33, a combination medication for the treatment of type 2 diabetes.

Type 2 diabetes can be very tricky and hard to control. Therefore, the discovery and approval of these new oral and injectable medications are important for healthcare providers and their patients.

What is Soliqua 100/33 indicated for?

Soliqua 100/33 is prescribed to improve glycemic control in adults with type 2 diabetes, in conjunction with diet and exercise. It is a combination of Lantus (insulin glargine) and Adlyxin (lixisenatide).

How does Soliqua 100/33 work?

The two active ingredients in Soliqua 100/33, Lantus and Adlyxin, work together to treat type 2 diabetes through different mechanisms:

Is there an advantage to using Soliqua 100/33?

Yes! Since Soliqua 100/33 is a combination drug, this means that patients only have to take one medication per-day, rather than two.

What dosage form(s) will Soliqua 100/33 be available in?

Soliqua 100/33 will be available in a package of 5 single-use, pre-filled, disposable pens.

How is Soliqua 100/33 administered?

Soliqua 100/33 is to be injected subcutaneously (under the skin) once daily, at least an hour before the 1st meal of the day.

What are the common side effects associate with Soliqua 100/33?

The most common side effects associated with Soliqua include: low blood sugar, diarrhea, allergic reactions, runny nose and sore throat, upper respiratory tract infections, nausea, and headache.

When will Soliqua 100/33 be available?

Soliqua was approved by the FDA on November 21st, 2016, but it not expected to be available in pharmacies until January 4th, 2017.

For more information, you can read the press announcement from the manufacturer, Sanofi here. You can also visit the manufacture website here.

Drugs featured in this story

Filed under